To,
The Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai - 400051

Date: 02-09-2026

Reference: Sheel Biotech Limited (Symbol/ISIN: SHEEL / INE0YJV01017)

Subject: Clarification with respect to Monitoring Agency Report for the half year ended March 31, 2026, submitted under Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to the Monitoring Agency Report for the half year ended March 31, 2026, issued by CARE Ratings Limited ("Monitoring Agency" / "MA"), submitted vide our letter dated August 31, 2026, we wish to place the following clarification on record for the information of shareholders and investors, so as to avoid any misinterpretation regarding utilisation of the Initial Public Offer (IPO) proceeds of the Company.

The Company confirms that out of the total issue proceeds of Rs. 3,402.00 Lakhs raised through the IPO, an amount of Rs. 3,128.37 Lakhs has been utilised as of March 31, 2026, in accordance with the objects stated in the Offer Document, with no deviation in the objects or the amount utilised. The unutilised balance of Rs. 273.63 Lakhs remains deployed in fixed deposits pending utilisation, as supported by a Statement of Utilisation of Issue Proceeds, a Management Certificate dated May 5, 2026 (Attached), and a Chartered Accountant's Certificate (attached) dated May 14, 2026 issued by Khatuwala & Associates, Chartered Accountants (UDIN: 26095038CUDGOO2820), all of which were furnished to the Monitoring Agency and have also been placed on record with the Exchange.

Summary of utilisation:

Particulars	Details
Name of the listed entity	Sheel Biotech Limited
Symbol / ISIN	SHEEL / INE0YJV01017
Amount Raised (Rs. Lakhs)	3,402.00
Funds Utilised (Rs. Lakhs)	3,128.37
Remaining Balance (Rs. Lakhs)	273.63 (deployed in fixed deposits, as disclosed)
Deviation in use of proceeds	No
CA Certificate on utilisation	Issued by Khatuwala & Associates, Chartered Accountants, dated May 14, 2026 (UDIN: 26095038CUDGOO2820)
Management Certificate on utilisation	Issued by the Company dated May 5, 2026

Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

Category	As per Offer Document (Rs. Lakhs)	Utilised (Rs. Lakhs)	Unutilised (Rs. Lakhs)
Funding capital expenditure requirements	911.95	665.95	246.00
Working Capital Requirements	1,588.00	1,588.00	-
General Corporate Purposes	476.80	472.17	4.63
Issue Related Expenses	425.25	402.25	23.00
Total	**3,402.00**	**3,128.37**	**273.63**

The Company clarifies that the Management Certificate and the Chartered Accountant's Certificate on utilisation of the IPO proceeds were duly prepared and furnished to the Monitoring Agency. The requisite CA Certificate on utilisation of IPO proceeds has been obtained and is enclosed herewith, and the matter has separately been clarified to NSE via email. The updated status of fund utilisation will be duly incorporated in the Monitoring Agency Report for the half year ending September 30, 2026

This clarification is issued in the interest of transparent and adequate disclosure to shareholders and investors of the Company.

You are requested to kindly take the above clarification on record.

Thanking you,
For and on behalf of Sheel Biotech Limited

Divye Chandak
Managing Director
DIN No- 07100902

To,

May 05, 2026

Care Rating Limited
9th Floor Berger,
Iconic Corenthum,
001/A2, Sector 16B,
Noida, Uttar Pradesh 201301

Sub.: Statement of utilisation of issue proceeds under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that the proceeds of the public Issue by the Company during the period of October 2025 to March 2026 have been utilised for the purpose for which these proceeds were raised in accordance with the respective Offer Documents of the issues.

A. Statement of the utilization of issue proceeds:

Particulars	Details
Mode of Fund Raising (Public issues/ Private placement	Public issues
Type of Instrument	Equity Shares
Date of Raising funds	08th October 2025
Amount Raised (In Rs. Lakhs)	3,402.00
Funds Utilised (In Rs. Lakhs)	3,128.37
Remaining Balances (In Rs. Lakhs)	273.63
Any Deviation (Yes / No)	No
If Yes, then specify the purpose for which the funds were utilised	No
Remarks, if any	No

Fund Utilized as below:

Category	Particulars	Amount (In Rs. Lakhs)
1. Funding capital expenditure requirements	For purchase of equipment/machineries and blueberries plants etc. to set up greenhouse facility for growing blueberries	665.95
2. Working Capital	Payment to Vendors, Salary and other operational Charges	1,588.00
3. General Corporate Purposes	Expenses for day to day activities of business	472.17
4. Issue Related Expenses	Payment of Expenses related to the right issue i.e Printing Fees, RTA Fee Etc	402.25
Total		**3,128.37**

B. Statement of deviation/ variation in the use of Issue proceeds:

Particulars	Details
Name of the listed entity	Sheel Biotech Limited
Mode of Fund Raising	Public Issue
Type of instrument	Equity Shares
Date of Raising Funds	As mentioned in the above table
Amount Raised	As mentioned in the above table
Is there a Deviation / Variation in the use of funds raised?	No
Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?	No
If yes, are details of the approval so required?	Not Applicable
Date of approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the audit committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table: Not Applicable, since there is no deviation.

Original Object	Modified Object, if any	Original allocation, if any	Modified Object, if any	Fund utilised	Amount of deviation/variation for the quarter according to the applicable object (in Rs. Crore and in %)	Remarks, if any
Not Applicable						

Deviation or variation could mean:
a) Deviation in the objects or purposes for which the funds have been raised or
b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc.

Other relevant information, is enclosed herewith as **Annexure – 1**.

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Figures in INR lakhs unless otherwise stated

Sr. No.	Particulars	Share Application A/c no. 925020026772251	Share Monitoring A/c no . 925020027591240	Supporting
	Total shares issued and subscribed as part IPO (No. of Units)		54,00,000	
1	Total proceeds received from issue	3,402.00		
2	Transfer from Allotment A/c to Monitoring A/c	2,999.75	2,999.75	
3	Amount in Allotment A/c and Monitoring A/c **(A)**	**402.25**	2,999.75	
4	Details of Expenses incurred related to issues **(B) (refer annexure 1)**	**402.25**	-	
5	Net proceeds available for utilisation **(C=A-B)**	-	**2,999.75**	
6	**Utilised Amount from proceed of IPO as at beginning of the half year:-**		-	
7	**Amount utilised of proceed from IPO during the half year:** a) H2FY26		2,726.12	
			2,726.12	
			2,726.12	
	8		**2,726.12**	
	9		245.32	
	10		**28.31**	

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Objects as per the offer documents

Figures in INR lakhs unless otherwise stated

Item head	Brief description of the object	Location of the object (if applicable)	Amount as per offer document in INR Lakhs	Amount utilised in INR Lakhs			Unutilised amount in INR Lakhs	Deviation, if any	Reasons for deviation
				As at beginning of the half year in INR Lakhs	During the half year in INR Lakhs	At the end of the half year in INR Lakhs			
Funding capital expenditure requirements	For purchase of equipment/machineries and blueberries plants etc. to set up greenhouse facility for growing blueberries		911.95	-	665.95	665.95	246.00	-	-
Working Capital Requirements			1,588.00	-	1,588.00	1,588.00	-	-	-
General Corporate Purposes			476.80	-	472.17	472.17	4.63	-	-
Issue Related Expenses			425.25	-	402.25	402.25	23.00	-	-
Total			**3,402.00**	**-**	**3,128.37**	**3,128.37**	**273.63**		

For and on Behalf of Sheel Biotech Limited

Divye Chandak
Managing Director
DIN NO- 07100902

Figures in INR lakhs unless otherwise stated

Sr. No	Item Head	Original cost (as per the Offer Document) in INR Lakhs	Revised Cost in INR Lakhs
1	Funding capital expenditure requirements	911.95	-
2	Working Capital Requirements	1,588.00	-
3	General Corporate Purposes	476.80	-
4	Issue Related Expenses	425.25	-
	Total	**3,402.00**	-

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Figures in INR lakhs unless otherwise stated

Progress in the object(s)

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in INR Lakhs		
			As at beginning of the half year	During the half year	At the end of the half year
1	Funding capital expenditure requirements	911.95	-	665.95	665.95
2	Working Capital Requirements	1,588.00	-	1,588.00	1,588.00
3	General Corporate Purposes	476.80	-	472.17	472.17
4	Issue Related Expenses	425.25	-	402.25	402.25
	Total	**3,402.00**	**-**	**3,128.37**	**3,128.37**

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Deployment of unutilised proceeds: **Figures in INR lakhs unless otherwise stated**

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter*
1	Axis FDR-925040105808329	100.00	08-11-2026	6.58	6.58%	106.58
2	Axis FDR-925040105827142	50.00	08-11-2026	3.29	6.58%	53.29
3	Axis FDR-925040105828970	100.00	09-11-2026	6.60	6.60%	106.60
4	Axis Monitoring a/c-925020027591240	28.31	NA	-	-	-

*Where the market value is not feasible, provide NAV/NRV/Book Value of the same

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Delay in implementation of the object(s), if any

Object(s)	Completion Date		Delay (no. of days/ months)
	As per the offer document	Actual*	
Funding capital expenditure requirements	FY26	Ongoing	Not ascertainable
Working Capital Requirements	FY26	Completed	Not ascertainable
General Corporate Purposes	FY26	Ongoing	Not ascertainable
Issue Related Expenses	FY26	Ongoing	Not ascertainable

*In case of continuing object(s), please specify latest/revised estimate of the completion date.

For and on Behalf of Sheel Biotech Limited

Divye Chandak
Managing Director
DIN NO- 07100902

Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head	Amount	Bank statements, auditor certificates and any other documents which substantiates the amount utilised
1	Payment to vendors	313.68	Bank Statement, Auditor Certificate and Management Certificate
2	Payment of salaries & wages	149.95	Bank Statement, Auditor Certificate and Management Certificate
3	Payment of freight expenses	8.54	Bank Statement, Auditor Certificate and Management Certificate
		472.17	

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Annexure-1 Figures in INR lakhs unless otherwise stated

Sr No	Vendor Name	Invoice Value	Payment Date
1	Narnolia Financial Services Limited	216.00	31.10.2025
2	Narnolia Financial Services Limited	167.43	01.11.2025
3	Madhur Press and Advertisement	3.39	02.11.2025
4	Prass & Associates LLP	0.41	03.11.2025
5	Skyline Financial Services Pvt Ltd	1.30	04.11.2025
6	IASH Marcom Ventures LLP	4.00	05.11.2025
7	Mansi Share and Stock Broking Pvt Ltd	9.72	06.11.2025
Total issue related expenses paid by company		**402.25**	

For and on Behalf of Sheel Biotech Limited

Divye Chandak
Managing Director
DIN NO- 07100902

Particulars	Information/documents required	Response
Whether all utilization is as per the disclosures in the Offer Document?	If yes, then please share bank statements, auditor certificates and any other documents which substantiates the utilisation as per the disclosures in the Offer Document	Yes document attached
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document, if any?	If yes, then please share board resolution and shareholders resolution authorizing the deviation	NA
Whether the means of finance for the disclosed objects of the issue have changed?	If yes, then please share board resolution authorizing the change in means of finance	No
Is there any major deviation* observed over the earlier monitoring agency reports?	If yes, then please provide the details wrt the same	NA
Whether all Government/statutory approvals related to the object(s) have been obtained?	If yes, then please share the approvals obtained. If no, please share the pending approvals and expected timelines of receiving the same.	Not required
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	If yes, then please share details of the same. If no, please share the pending technical assistance/collaboration and expected timelines of finalising the same.	Not required
Are there any favorable/unfavorable events affecting the viability of these object(s)?	If yes, then please share	No
Is there any other relevant information that may materially affect the decision making of the investors?	If yes, then please share	No
*Where material deviation may be defined to mean: (a) Deviation in the objects or purposes for which the funds have been raised (b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.		

For and on Behalf of Sheel Biotech Limited

SHEEL BIOTECH LTD. New Delhi

Divye Chandak
Managing Director
DIN NO- 07100902

Khatuwala Associates
Chartered Accountants

Delhi Office : 13L, Gopala Tower, 25 Rajendra Place, New Delhi - 110008
Tel.: +91-11-41538276, 41536621 | Mob. : +91-9891463326
Kundli Office : SCO 37, HSIIDC Commercial Complex, Kundli Industrial Area, Kundli - 131028, Sonipat, Haryana
Tel. : +91-0130-4012959 | Mob. : +91-8287978249
E-mail : info@khatuwala.net
URL : www.khatuwala.net

To,
Care Rating Limited
9th Floor Berger,
Iconic Corenthum,
001/A2, Sector 16B,
Noida, Uttar Pradesh 201301

May 14, 2026

Sub.: Statement of utilisation of issue proceeds under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that the proceeds of the public Issue by the Company during the period of October 2025 to March 2026 have been utilised for the purpose for which these proceeds were raised in accordance with the respective Offer Documents of the issues.

A. Statement of the utilization of issue proceeds:

Particulars	Details
Mode of Fund Raising (Public issues/ Private placement	Public issues
Type of Instrument	Equity Shares
Date of Raising funds	08th October 2025
Amount Raised (In Rs. Lakhs)	3,402.00
Funds Utilised (In Rs. Lakhs)	3,128.37
Remaining Balances (In Rs. Lakhs)	273.63
Any Deviation (Yes / No)	No
If Yes, then specify the purpose for which the funds were utilised	No
Remarks, if any	No

Fund Utilized as below:

Category	Particulars	Amount (In Rs. Lakhs)
1. Funding capital expenditure requirements	For purchase of equipment/machineries and blueberries plants etc. to set up greenhouse facility for growing blueberries	665.95
2. Working Capital	Payment to Vendors, Salary and other operational Charges	1,588.00
3. General Corporate Purposes	Expenses for day to day activities of business	472.17
4. Issue Related Expenses	Payment of Expenses related to the right issue i.e Printing Fees, RTA Fee Etc	402.25
Total		**3,128.37**

Khatuwala & Associates New Delhi Chartered Accountants

INDIA

Khatuwala Associates
Chartered Accountants

Delhi Office : 13L, Gopala Tower, 25
Rajendra Place, New Delhi - 110008
Tel.: +91-11-41538276, 41536621 | Mob. : +91-9891463326
Kundli Office : SCO 37, HSIIDC Commercial Complex,
Kundli Industrial Area, Kundli - 131028,
Sonipat, Haryana
Tel. : +91-0130-4012959 | Mob. : +91-8287978249
E-mail : info@khatuwala.net
URL : www.khatuwala.net

B. Statement of deviation/ variation in the use of Issue proceeds:

Particulars	Details
Name of the listed entity	Sheel Biotech Limited
Mode of Fund Raising	Public Issue
Type of instrument	Equity Shares
Date of Raising Funds	As mentioned in the above table
Amount Raised	As mentioned in the above table
Is there a Deviation / Variation in the use of funds raised?	No
Whether any approval is required to vary the objects of the issue stated in the prospectus/ offer document?	No
If yes, are details of the approval so required?	Not Applicable
Date of approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the audit committee after review	None
Comments of the auditors, if any	None

Objects for which funds have been raised and where there has been a deviation, in the following table: Not Applicable, since there is no deviation.

Original Object	Modified Object, if any	Original allocation, if any	Modified Object, if any	Fund utilised	Amount of deviation/variation for the quarter according to the applicable object (in Rs. Crore and in %)	Remarks, if any
Not Applicable						

Deviation or variation could mean:

a) Deviation in the objects or purposes for which the funds have been raised or

b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

c) Change in terms of a contract referred to in the fund-raising document i.e., prospectus, letter of offer, etc.

Khatuwala & Associates
New Delhi
Chartered Accountants

Khatuwala Associates
Chartered Accountants

Delhi Office : 13L, Gopala Tower, 25
Rajendra Place, New Delhi - 110008
Tel.: +91-11-41538276, 41536621 | Mob. : +91-9891463326
Kundli Office : SCO 37, HSIIDC Commercial Complex,
Kundli Industrial Area, Kundli - 131028,
Sonipat, Haryana
Tel. : +91-0130-4012959 | Mob. : +91-8287978249
E-mail : info@khatuwala.net
URL : www.khatuwala.net

Other relevant information is enclosed herewith as **Annexure – 1**.

CA Raman Khatuwala
Membership No: 095038

For and on behalf of
KHATUWALA & ASSOCIATES
Chartered Accountants
(Registration No .015735N)

Date: 15th May 2026
Place: New Delhi
UDIN: 26095038CUDGOO2820

Khatuwala & Associates
New Delhi
Chartered Accountants

Figures in INR lakhs unless otherwise stated

Sr. No.	Particulars	Share Application A/c no. 925020026772251	Share Monitoring A/c no. 925020027591240	Supporting
	Total shares issued and subscribed as part IPO (No. of Units)		54,00,000	
1	Total proceeds received from issue	3,402.00		
2	Transfer from Allotment A/c to Monitoring A/c	2,999.75	2,999.75	
3	Amount in Allotment A/c and Monitoring A/c **(A)**	**402.25**	2,999.75	
4	Details of Expenses incurred related to issues **(B) (refer annexure 1)**	**402.25**	-	
5	Net proceeds available for utilisation **(C=A-B)**	-	**2,999.75**	
6	**Utilised Amount from proceed of IPO as at beginning of the half year:-**		-	
7	**Amount utilised of proceed from IPO during the half year:**			
	a) H2FY26		2,726.12	
			2,726.12	
			2,726.12	
	8		**2,726.12**	
	9		245.32	
	10		**28.31**	

CA Raman Khatuwala
Membership No : 095038

For and on behalf of
KHATUWALA & ASSOCIATES
Chartered Accountants
(Registration No .015735N)

Khatuwala & Associates New Delhi Chartered Accountants

Date: 15th May 2026
Place: New Delhi
UDIN: 26095038CUDGOO2820

Objects as per the offer documents

Figures in INR lakhs unless otherwise stated

Item head	Brief description of the object	Location of the object (if applicable)	Amount as per offer document in INR Lakhs	Amount utilised in INR Lakhs			Unutilised amount in INR Lakhs	Deviation, if any	Reasons for deviation
				As at beginning of the half year in INR Lakhs	During the half year in INR Lakhs	At the end of the half year in INR Lakhs			
Funding capital expenditure requirements	For purchase of equipment/machineries and blueberries plants etc. to set up greenhouse facility for growing blueberries		911.95	-	665.95	665.95	246.00	-	-
Working Capital Requirements			1,588.00	-	1,588.00	1,588.00	-	-	-
General Corporate Purposes			476.80	-	472.17	472.17	4.63	-	-
Issue Related Expenses			425.25	-	402.25	402.25	23.00	-	-
Total			3,402.00	-	3,128.37	3,128.37	273.63		

CA Raman Khatuwala
Membership No : 095038

For and on behalf of
KHATUWALA & ASSOCIATES
Chartered Accountants
(Registration No .015735N)

Date: 15th May 2026
Place: New Delhi
UDIN: 26095038CUDGOO2820

Khatuwala & Associates New Delhi Chartered Accountants

Figures in INR lakhs unless otherwise stated

Sr. No	Item Head	Original cost (as per the Offer Document) in INR Lakhs	Revised Cost in INR Lakhs
1	Funding capital expenditure requirements	911.95	-
2	Working Capital Requirements	1,588.00	-
3	General Corporate Purposes	476.80	-
4	Issue Related Expenses	425.25	-
	Total	**3,402.00**	-

Khatuwala & Associates ★ Chartered Accountants ★ New Delhi

Figures in INR lakhs unless otherwise stated

Progress in the object(s)

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized in INR Lakhs		
			As at beginning of the half year	During the half year	At the end of the half year
	Funding capital expenditure requirements	911.95	-	665.95	665.95
	Working Capital Requirements	1,588.00	-	1,588.00	1,588.00
	General Corporate Purposes	476.80	-	472.17	472.17
	Issue Related Expenses	425.25	-	402.25	402.25
	Total	**3,402.00**	-	**3,128.37**	**3,128.37**

Khatuwala & Associates Chartered Accountants New Delhi

Deployment of unutilised proceeds: **Figures in INR lakhs unless otherwise stated**

Sr. No.	Type of instrument and name of the entity invested in	Amount invested	Maturity date	Earning	Return on Investment (%)	Market Value as at the end of quarter*
1	Axis FDR- 925040105808329	100.00	08/11/26	6.58	6.58%	106.58
2	Axis FDR- 925040105827142	50.00	08/11/26	3.29	6.58%	53.29
3	Axis FDR-925040105828970	100.00	09/11/26	6.60	6.60%	106.60
4	Axis Monitoring a/c- 925020027591240	28.31	NA	-	-	-

*Where the market value is not feasible, provide NAV/NRV/Book Value of the same

Khandelwala & Associates Chartered Accountants New Delhi

Delay in implementation of the object(s), if any

Object(s)	Completion Date		Delay (no. of days/ months)
	As per the offer document	Actual*	
Funding capital expenditure requirements	FY26	Ongoing	Not ascertainable
Working Capital Requirements	FY26	Completed	Not ascertainable
General Corporate Purposes	FY26	Ongoing	Not ascertainable
Issue Related Expenses	FY26	Ongoing	Not ascertainable

*In case of continuing object(s), please specify latest/revised estimate of the completion date.

Khatuwala & Associates
Chartered Accountants
New Delhi

Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head	Amount	Bank statements, auditor certificates and any other documents which substantiates the amount utilised
1	Payment to vendors	313.68	Bank Statement, Auditor Certificate and Management Certificate
2	Payment of salaries & wages	149.95	Bank Statement, Auditor Certificate and Management Certificate
3	Payment of freight expenses	8.54	Bank Statement, Auditor Certificate and Management Certificate
		472.17	

Annexure-1

Figures in INR lakhs unless otherwise stated

Sr N	Vendor Name	Invoice Value	Payment Date
1	Narnolia Financial Services Limited	216.00	31.10.2025
2	Narnolia Financial Services Limited	167.43	01.11.2025
3	Madhur Press and Advertisement	3.39	02.11.2025
4	Prass & Associates LLP	0.41	03.11.2025
5	Skyline Financial Services Pvt Ltd	1.30	04.11.2025
6	IASH Marcom Ventures LLP	4.00	05.11.2025
7	Mansi Share and Stock Broking Pvt Ltd	9.72	06.11.2025
	Total issue related expenses paid by company	402.25	

Khacuwala & Associates
New Delhi

Particulars	Information/documents required	Response
Whether all utilization is as per the disclosures in the Offer Document?	If yes, then please share bank statements, auditor certificates and any other documents which substantiates the utilisation as per the disclosures in the Offer Document	Yes document attached
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document, if any?	If yes, then please share board resolution and shareholders resolution authorizing the deviation	NA
Whether the means of finance for the disclosed objects of the issue have changed?	If yes, then please share board resolution authorizing the change in means of finance	No
Is there any major deviation* observed over the earlier monitoring agency reports?	If yes, then please provide the details wrt the same	NA
Whether all Government/statutory approvals related to the object(s) have been obtained?	If yes, then please share the approvals obtained. If no, please share the pending approvals and expected timelines of receiving the same.	Not required
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	If yes, then please share details of the same. If no, please share the pending technical assistance/collaboration and expected timelines of finalising the same.	Not required
Are there any favorable/unfavorable events affecting the viability of these object(s)?	If yes, then please share	No
Is there any other relevant information that may materially affect the decision making of the investors?	If yes, then please share	No
*Where material deviation may be defined to mean: (a) Deviation in the objects or purposes for which the funds have been raised (b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.		